MX2023009238A - Nuevos anticuerpos anti-cd24. - Google Patents

Nuevos anticuerpos anti-cd24.

Info

Publication number
MX2023009238A
MX2023009238A MX2023009238A MX2023009238A MX2023009238A MX 2023009238 A MX2023009238 A MX 2023009238A MX 2023009238 A MX2023009238 A MX 2023009238A MX 2023009238 A MX2023009238 A MX 2023009238A MX 2023009238 A MX2023009238 A MX 2023009238A
Authority
MX
Mexico
Prior art keywords
antibodies
novel anti
pharmaceutical compositions
present description
same
Prior art date
Application number
MX2023009238A
Other languages
English (en)
Spanish (es)
Inventor
Yun Liu
Bo Shan
Bing Hou
Peng Chen
Hui Yuwen
Jay Mei
Min Deng
Jiamei Luo
Original Assignee
Antengene Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Biologics Ltd filed Critical Antengene Biologics Ltd
Publication of MX2023009238A publication Critical patent/MX2023009238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2023009238A 2021-02-08 2022-02-08 Nuevos anticuerpos anti-cd24. MX2023009238A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021076075 2021-02-08
CN202210088172 2022-01-25
PCT/US2022/015711 WO2022170280A2 (en) 2021-02-08 2022-02-08 Novel anti-cd24 antibodies

Publications (1)

Publication Number Publication Date
MX2023009238A true MX2023009238A (es) 2023-08-16

Family

ID=82741874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009238A MX2023009238A (es) 2021-02-08 2022-02-08 Nuevos anticuerpos anti-cd24.

Country Status (11)

Country Link
US (1) US20240052052A1 (enExample)
EP (1) EP4288099A4 (enExample)
JP (1) JP2024508672A (enExample)
KR (1) KR20230143177A (enExample)
CN (1) CN117412770A (enExample)
AU (1) AU2022217072A1 (enExample)
CA (1) CA3210934A1 (enExample)
CO (1) CO2023011463A2 (enExample)
IL (1) IL304898A (enExample)
MX (1) MX2023009238A (enExample)
WO (1) WO2022170280A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121311506A (zh) * 2023-06-09 2026-01-09 天境生物科技(上海)有限公司 抗-cd24抗体及其用途
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
TW202535944A (zh) * 2023-11-08 2025-09-16 美商飛斯特醫療公司 Ｃｄ２４抗體
WO2025128830A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Therapeutic lilrb regulation for treating neurological disorders
AU2024402617A1 (en) * 2023-12-19 2026-05-14 Pentixapharm Ag Antibodies against cd24
WO2025159754A1 (en) * 2024-01-25 2025-07-31 China Medical University Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use
WO2025218729A1 (en) * 2024-04-17 2025-10-23 TJ Biopharma (Shanghai) Co., Ltd. Multifunctional molecules targeting cd24
CN119161485B (zh) * 2024-10-29 2026-03-24 上海中医药大学附属曙光医院 靶向GFRα3的抗体及其制备方法和在抗癌中的应用
WO2026117619A1 (en) * 2024-11-26 2026-06-04 Pheast Therapeutics, Inc. Cd24-binding antibodies
WO2026130747A1 (en) * 2024-12-19 2026-06-25 Pentixapharm Ag Antibodies against cd24

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
WO2015200522A2 (en) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
SG11202010589YA (en) * 2018-05-14 2020-11-27 Oncoimmune Inc Anti-cd24 compositions and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
JP2022538870A (ja) * 2019-06-25 2022-09-06 イチロフ テック リミテッド 抗ｃｄ２４抗体及びその使用

Also Published As

Publication number Publication date
AU2022217072A9 (en) 2024-01-18
TW202241956A (zh) 2022-11-01
EP4288099A2 (en) 2023-12-13
CO2023011463A2 (es) 2023-09-18
CA3210934A1 (en) 2022-08-11
US20240052052A1 (en) 2024-02-15
KR20230143177A (ko) 2023-10-11
WO2022170280A3 (en) 2022-09-09
IL304898A (en) 2023-10-01
AU2022217072A1 (en) 2023-10-05
JP2024508672A (ja) 2024-02-28
EP4288099A4 (en) 2025-09-17
WO2022170280A2 (en) 2022-08-11
CN117412770A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
CO2023011463A2 (es) Nuevos anticuerpos anti-cd24
CO2023018064A2 (es) Anticuerpos anti-ccr8 y usos de los mismos
AR120883A1 (es) Anticuerpos anti-fgfr2b
AR120886A1 (es) Anticuerpos anti-fgfr2b
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
CO2024013551A2 (es) Nuevos anticuerpos anti-cd3 y usos de los mismos
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR120884A1 (es) Anticuerpos anti-fgfr2b
PE20241349A1 (es) Anticuerpos de union a cd3
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
CL2022003515A1 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
CL2010000791A1 (es) Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03)
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
BR112021026133A2 (pt) Anticorpo anti-cd24 e usos do mesmo
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
AR054474A1 (es) Formulacion de anticuerpos estables
DOP2023000005A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CO2023015915A2 (es) Anticuerpos anti-ccr8
MX2024015391A (es) Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico
CO2024003577A2 (es) Anticuerpos del receptor antitransferrina y usos de los mismos